Get the Stockscreener App
1.34
2.29%
0.03
After Hours:
1.34
Spero Therapeutics Inc stock is traded at $1.34, with a volume of 76,915.
It is up +2.29% in the last 24 hours and down -2.19% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$1.31
Open:
$1.31
24h Volume:
76,915
Relative Volume:
0.69
Market Cap:
$72.43M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
-5.1538
EPS:
-0.26
Net Cash Flow:
$28.98M
1W Performance:
+3.08%
1M Performance:
-2.19%
6M Performance:
-22.09%
1Y Performance:
+10.74%
1-Day Range:
$1.305
$1.3899
1-Week Range:
$1.24
$1.3899
52-Week Range:
$0.99
$1.89
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below 200-Day Moving Average of $1.46 - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200-Day Moving Average of $1.48 - MarketBeat
Spero Therapeutics Details Pipeline Progress and Future Goals - TipRanks
Spero Therapeutics to Present at Upcoming September Investor Conferences - GlobeNewswire
Spero Therapeutics to Present at Upcoming September Investor Conferences - StockTitan
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200-Day Moving Average of $1.49 - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200-Day Moving Average of $1.49 - Defense World
Spero Therapeutics COO sells $2,987 in company stock By Investing.com - Investing.com South Africa
Spero Therapeutics CEO sells shares worth over $3.7k By Investing.com - Investing.com Canada
Spero therapeutics director sells shares worth $7,981 - Investing.com India
Spero Therapeutics COO sells $2,987 in company stock - Investing.com
Spero Therapeutics CEO sells shares worth over $3.7k By Investing.com - Investing.com UK
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200 Day Moving Average of $1.49 - Defense World
Spero Therapeutics (STU:2HA) Enterprise Value : €9.12 Mil (As of Aug. 20, 2024) - GuruFocus.com
Spero Therapeutics (STU:2HA) Total Assets : €139.24 Mil (As of Jun. 2024) - GuruFocus.com
Spero Therapeutics (STU:2HA) Debt-to-Revenue : 0.21 (As of Jun. 2024) - GuruFocus.com
Spero Therapeutics (STU:2HA) Financial Strength : 6 (As of Jun. 2024) - GuruFocus.com
SPRO (Spero Therapeutics) Total Liabilities : $69.4 Mil (As of Jun. 2024) - GuruFocus.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Spero Therapeutics Q2 2024 update highlights pipeline progress - Investing.com
Earnings call: Spero Therapeutics Q2 2024 update highlights pipeline progress - Investing.com Canada
Spero Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.38) Per Share, HC Wainwright Forecasts (NASDAQ:SPRO) - MarketBeat
Virtu Financial LLC Purchases New Holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript - Seeking Alpha
HC Wainwright Analysts Reduce Earnings Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.38) Per Share (NASDAQ:SPRO) - American Banking and Market News
HC Wainwright Weighs in on Spero Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:SPRO) - Defense World
FY2024 Earnings Forecast for Spero Therapeutics, Inc. Issued By Cantor Fitzgerald (NASDAQ:SPRO) - Defense World
Spero Therapeutics, Inc. (NASDAQ:SPRO) Forecasted to Post Q1 2025 Earnings of ($0.38) Per Share - MarketBeat
Spero Therapeutics Inc’s latest rating changes from various analysts - Knox Daily
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Expectations By $0.01 EPS - Defense World
Spero Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla Sells 14,800 Shares of Stock - Defense World
Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla Sells 17,641 Shares - Defense World
Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla Sells 14,800 Shares of Stock - American Banking and Market News
Spero Therapeutics (NASDAQ:SPRO) Upgraded to “Buy” by TD Cowen - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Spero Therapeutics (NASDAQ:SPRO) - Defense World
Spero Therapeutics (NASDAQ:SPRO) Receives Overweight Rating from Cantor Fitzgerald - American Banking and Market News
Spero Therapeutics’ (SPRO) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Sath Shukla Sells 14,800 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock - MarketBeat
Spero Therapeutics CEO sells over $42k in company stock - Investing.com
Spero Therapeutics CEO sells over $42k in company stock By Investing.com - Investing.com Canada
Spero Therapeutics (NASDAQ:SPRO) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Raised to Buy at TD Cowen - MarketBeat
Spero Therapeutics Inc (SPRO) Q2 2024 Earnings Call Transcript H - GuruFocus.com
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update - ForexTV.com
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates - MSN
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance UK
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update - wallstreet:online
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics (SPRO) Scheduled to Post Earnings on Monday - American Banking and Market News
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):